Edition:
United Kingdom

Sun Pharmaceutical Industries Ltd (SUN.BO)

SUN.BO on Bombay Stock Exchange

464.70INR
18 May 2018
Change (% chg)

Rs-15.40 (-3.21%)
Prev Close
Rs480.10
Open
Rs489.70
Day's High
Rs489.70
Day's Low
Rs463.00
Volume
534,715
Avg. Vol
552,977
52-wk High
Rs656.75
52-wk Low
Rs433.15

Chart for

About

Sun Pharmaceutical Industries Limited is a pharmaceuticals company. The Company's business segments include US Business, Indian Branded Generics Business, Emerging Markets, Global Consumer Healthcare Business and Active Pharmaceutical Ingredients (API). Its Rest of World segment includes Western Europe, Canada, Australia, New... (more)

Overall

Beta: 0.05
Market Cap(Mil.): Rs1,272,113.00
Shares Outstanding(Mil.): 2,399.31
Dividend: 3.50
Yield (%): 0.66

Financials

  SUN.BO Industry Sector
P/E (TTM): 28.37 30.95 32.75
EPS (TTM): 18.69 -- --
ROI: -- 14.84 14.38
ROE: -- 16.34 16.07

BRIEF-Sun Pharmaceutical Industries' Unit Raises Stake In Ranbaxy Malaysia

* UNIT RAISED STAKE IN RANBAXY MALAYSIA VIA FURTHER PURCHASE OF 394,404 SHARES OF RANBAXY MALAYSIA

18 Apr 2018

BRIEF-Sun Pharmaceutical Industries Gets U.S. FDA Nod Of ILUMYA (Tildrakizumab-Asmn)

* CO GETS U.S. FDA APPROVAL OF ILUMYA (TILDRAKIZUMAB-ASMN) FOR TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS Source text - http://bit.ly/2HRX8j1 Further company coverage:

21 Mar 2018

BRIEF-Sun Pharmaceutical Industries Says U.S. FDA Issued Form 483 With 3 Observations For Halol Facility

* SUN PHARMACEUTICAL INDUSTRIES -U.S. FDA CONDUCTED GMP INSPECTION OF HALOL FACILITY (GUJARAT, INDIA) FROM FEBRUARY 12-23, 2018

23 Feb 2018

UPDATE 1-India's Sun Pharma quarterly profit plunges on weak U.S. sales

* Profit hit by one-time deferred tax adjustment (Adds details)

14 Feb 2018

BRIEF-Sun Pharma Industries Says Qtrly US Finished Dosage Sales Down 35 Pct

* SAYS US FINISHED DOSAGE SALES DURING QUARTER AT US$ 328 MILLION, DOWN 35 PERCENT OVER Q3 LAST YEAR Source text for Eikon: Further company coverage:

14 Feb 2018

India's Sun Pharma Q3 profit slides 75 pct, misses estimates

Feb 14 India's largest drugmaker Sun Pharmaceutical Industries Ltd reported on Wednesday a 75 percent drop in net profit in the quarter ending Dec. 31, well below analysts' estimates.

14 Feb 2018

BRIEF-India's Sun Pharmaceutical Industries Dec-Qtr Consol Profit Down 75 Pct

* DEC QUARTER CONSOL NET PROFIT AFTER TAX 3.65 BILLION RUPEES VERSUS PROFIT OF 14.72 BILLION RUPEES LAST YEAR

14 Feb 2018

BRIEF-Allergan, Ironwood Announce Settlement With Sun Pharma

* IRONWOOD AND ALLERGAN ANNOUNCE SETTLEMENT WITH SUN PHARMA RESOLVING LINZESS® (LINACLOTIDE) PATENT LITIGATION

16 Jan 2018

Indian shares hit record highs for 3rd straight session

Dec 27 Indian shares touched record highs for a third consecutive session on Wednesday, with investors picking pharma stocks such as Sun Pharmaceutical Industries Ltd that have lagged a broader market rally this year.

27 Dec 2017

BRIEF-Sun Pharmaceutical Industries Announces U.S FDA Acceptance Of NDA For OTX-101

* ANNOUNCES U.S FDA ACCEPTANCE OF NDA FOR OTX-101 Source text - http://bit.ly/2BDUZEZ Further company coverage:

27 Dec 2017

Earnings vs. Estimates